Comparative Diagnostic performance of Alpha-1-Antitrypsin and AFP in the detection of hepatocellular carcinoma
Not Applicable
- Conditions
- Investigate the role of Alpha -1- antitrypsin (A1AT) and Alpha-Fetoprotein (AFP) in hepatocellular carcinoma among Iraqi patients..Alpha-1-antitrypsin deficiency,E88.01
- Registration Number
- IRCT20230813059136N1
- Lead Sponsor
- niversity of Sousse
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
This case-control study was conducted on 100 HCC patients being treated at the National Liver Institute Hospital, Baghdad University, Iraq. All of the participants were Iraqis. As control subjects, 100 age- and sex-matched healthy blood donors with no history of malignant or genetic diseases provided blood samples. Until analysis, blood and plasma samples were kept at 80 °C.
Exclusion Criteria
Individuals with a documented medical history of malignancy and genetic disorders were not included in the study.
Individuals with a higher incidence of the disease in regions other than the liver were excluded from the study.
Exclusions were made for patients who expired within the duration of the research.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Alpha -1- antitrypsin. Timepoint: Before intervention and 10 weeks after intervention. Method of measurement: The plasma A1AT level was measured by nephelometry using commercially available antibodies (MININEPH, Birmingham, UK), with an Array™ Protein System autoanalyzer (Beckman Instruments, Brea, California, USA).
- Secondary Outcome Measures
Name Time Method